BIOCON LTD.

Biocon Limited has announced a significant 10-year supply contract for Pertuzumab in Brazil, a HER2-positive breast cancer therapy. This agreement, part of Brazil's Productive Development Partnership (PDP) program, is a collaboration with Bahiafarma and Bionovis. The consortium secured 100% allocation in the PDP, granting exclusive access to Brazil's public healthcare market, which represents approximately 70% of the country's demand for Pertuzumab. Biocon will benefit from milestone payments and a share of revenues over the contract period. The partnership also includes phased localization of the product in Brazil, aiming to enhance local manufacturing capabilities and expand access to this critical cancer treatment within the Unified Health System (SUS).

Biocon Ltd has announced the remittance of its final dividend for the financial year 2025-26. The dividend, approved at the 48th Annual General Meeting held on August 6, 2026, amounts to ₹0.50 per equity share (face value ₹5). Shareholders whose email addresses are registered with the RTA or Depository Participants have received the dividend electronically. The company has also informed shareholders to verify the credit in their bank accounts and to contact KFin Technologies Limited, the Registrar & Share Transfer Agent, in case of any discrepancies.

Biocon Ltd has received a revised disclosure from Mylan Inc. concerning the sale of 9,19,67,019 equity shares, representing 5.64% of Biocon's equity share capital. Mylan Inc. clarified that the post-disposal shareholding was inadvertently disclosed as 5.64% instead of the correct value of Nil. This filing serves solely to rectify a typographical error in the original disclosure made on July 15, 2026, regarding a sale that occurred on July 14, 2026. All other information in the original disclosure remains unchanged.

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has received marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). The biosimilar, a substitute for Neulasta®, was developed and manufactured by Biocon Biologics. Global Regulatory Partners Japan will act as the Marketing Authorization Holder, while Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan. This approval expands Biocon's biosimilar offerings in Japan and underscores its commitment to global patient access to affordable medications.

Biocon Limited's US subsidiary has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek® (ustekinumab-kfce) in both 45 mg/0.5 ml and 90 mg/ml single-dose prefilled autoinjector formats. This approval, building on the original approval from November 29, 2024, offers patients an additional treatment option for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. The new delivery format aims to provide more tailored treatment approaches and enhances Biocon's immunology product portfolio in the US, reinforcing its commitment to affordable medicine access.

Biocon Ltd announced changes following its 48th Annual General Meeting (AGM) held on August 6, 2026. The company's statutory auditors, B S R & Co. LLP, completed their tenure. S.R. Batliboi & Associates LLP has been appointed as the new statutory auditors for a term of five consecutive years, concluding at the 53rd AGM in 2031. Additionally, Mr. Eric Vivek Mazumdar was re-appointed as a Director liable to retire by rotation, and Mr. Nicholas Robert Haggar ceased to be an Independent Director upon completing his term. The company confirmed Mr. Mazumdar is not debarred from holding office by any regulatory authority.

Biocon Ltd announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM) held on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as Director liable to retire by rotation. The company also appointed S.R. Batliboi & Associates LLP as its new Statutory Auditors for a five-year term, replacing B S R & Co. LLP whose term expired. Additionally, Mr. Nicholas Robert Haggar retired as an Independent Director upon completion of his term. Mr. Mazumdar's profile highlights his academic background in AI, machine learning, and economics.

Biocon Ltd announced changes in its directorate and statutory auditors at its 48th Annual General Meeting (AGM) held on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a Director liable to retire by rotation. The company also appointed S.R. Batliboi & Associates LLP as its new Statutory Auditors for a five-year term, succeeding B S R & Co. LLP whose term expired. Additionally, Mr. Nicholas Robert Haggar retired as an Independent Director upon completion of his term. The filing confirms Mr. Mazumdar is not debarred by SEBI and provides detailed profiles for the new auditor and director.

Biocon Ltd announced changes following its 48th Annual General Meeting (AGM) held on August 6, 2026. The company re-appointed Mr. Eric Vivek Mazumdar as Director liable to retire by rotation. B S R & Co. LLP retired as Statutory Auditors upon completion of their term. S.R. Batliboi & Associates LLP has been appointed as the new Statutory Auditors for a term of five consecutive years, from the conclusion of the 48th AGM until the 53rd AGM in 2031. Additionally, Mr. Nicholas Robert Haggar retired as an Independent Director after completing his term. The company confirmed Mr. Mazumdar is not debarred from holding office by any SEBI order.

Biocon Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. Total income rose 9% year-on-year to ₹4,391 crore, while EBITDA stood at ₹902 crore with a 21% margin. Net profit after exceptional items was ₹141 crore, a significant increase from ₹31 crore in the prior year quarter. The Biopharma segment showed strong growth, with revenue up 17% year-on-year, driven by biosimilar and generic product launches. Biosimilars revenue grew 16% to ₹2,855 crore, and Generics revenue increased 21% to ₹760 crore. Services revenue saw a 16% decrease to ₹736 crore. The company highlighted strategic investments, favorable policy for biosimilars, expanded manufacturing capabilities, and successful product launches in key markets like the U.S. Interest costs were reduced by 23% due to balance sheet strengthening measures.